Bi-level Positive Airway Pressure Devices (BiPAP) Market - 2026-2033
Bi-level Positive Airway Pressure Devices (BiPAP) Market reached US$1.45 Billion in 2024 and is expected to reach US$3.70 Billion by 2033, growing with a CAGR of 5.50% during the forecast period 2026-2033.
The Bi-level Positive Airway Pressure Devices (BiPAP) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Bi-level Positive Airway Pressure Devices (BiPAP) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product
Both primary and secondary data sources have been used in the global Bi-level Positive Airway Pressure Devices (BiPAP) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Bi-level Positive Airway Pressure Devices (BiPAP) Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Bi-level Positive Airway Pressure Devices (BiPAP) Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product
- Devices*
- Fixed Pressure BiPAP Devices
- Auto-adjusting BiPAP Devices
- BiPAP ST (Spontaneous/Timed) Devices
- BiPAP AVAPS Devices
- Portable / Travel BiPAP Devices
- ICU / Critical Care BiPAP Systems
- Pediatric / Neonatal BiPAP Devices
- Others
- Masks
- Full Face Masks
- Nasal Masks
- Nasal Pillow Masks
- Total Face Masks
- Pediatric Masks
- Aftermarket Parts and Accessories
- Tubing / Breathing Circuits
- Humidifiers
- Filters
- Headgear and Straps
- Cushions and Mask Liners
- Water Chambers
- Batteries and Power Adapters
- Carrying Cases
- Obstructive Sleep Apnea*
- Central Sleep Apnea
- Complex Sleep Apnea
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Failure
- Chronic Respiratory Failure
- Neuromuscular Disorders
- Obesity Hypoventilation Syndrome
- Pneumonia and Other Respiratory Infections
- Post-operative Respiratory Support
- Others
- Integrated Humidification*
- Heated Tubing
- Smart Connectivity
- Bluetooth-enabled Devices
- Wi-Fi-enabled Devices
- Cloud-based Monitoring
- Telemonitoring Compatible Devices
- Noise Reduction Technology
- Pressure Relief Technology
- Leak Compensation Systems
- Touchscreen / Digital Interface
- Others
- Stationary Devices*
- Portable Devices
- Travel-friendly Devices
- Others
- Adult*
- Pediatric
- Geriatric
- Hospitals*
- Academic / Teaching Hospitals
- Sleep Clinics and Sleep Laboratories
- Home Healthcare Settings
- Ambulatory Surgical Centers
- Long-term Care Facilities
- Rehabilitation Centers
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Bi-level Positive Airway Pressure Devices (BiPAP) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. DEFINITION AND OVERVIEW
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. EXECUTIVE SUMMARY
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising prevalence of psychiatric disorders and substance-induced agitation
3.1.1.2. Increasing emergency department visits related to acute behavioral disturbances
3.1.1.3. Growing adoption of rapid-acting and novel drug delivery formulations
3.1.2. Restraints
3.1.2.1. Safety concerns and adverse effects associated with antipsychotics and sedatives
3.1.2.2. Stringent regulatory scrutiny and post-marketing safety requirements
3.1.3. Opportunity
3.1.3.1. Development of non-invasive and fast-acting delivery systems (inhaled, intranasal, sublingual)
3.1.3.2. Increasing demand in emerging markets due to improving psychiatric care access
3.1.3.3. Pipeline development targeting agitation in dementia and Alzheimer’s disease
3.1.4. Trends
3.1.4.1. Shift toward atypical antipsychotics with improved safety profiles
3.1.4.2. Increasing preference for rapid-onset formulations in emergency psychiatry
3.1.5. Impact Analysis
4. INDUSTRY ANALYSIS
4.1. Porter’s Five Force Analysis – Global Bi-level Positive Airway Pressure Devices (BiPAP)
4.2. Geopolitical & Supply Chain Exposure
4.2.1. API Sourcing Concentration for Antipsychotics and Benzodiazepines
4.2.2. Trade Policies, Export Controls, and Psychiatric Drug Supply Risks
4.3. Social & Patient-Centric Factors
4.3.1. Physician Prescribing Behavior in Emergency Psychiatry and Acute Care
4.3.2. Brand Preference vs Generic Substitution Across Antipsychotics and Sedatives
4.3.3. Patient and Caregiver Concerns Regarding Sedation, Safety, and Monitoring
4.3.4. Awareness Gaps in Early Recognition and Management of Acute Agitation
4.4. Economic Factors
4.4.1. Reimbursement and Coverage in Hospital and Emergency Care Settings
4.4.2. Inflationary Pressure on APIs, Sterile Injectables, and CNS Drug Manufacturing
4.4.3. Currency Volatility Impacting Export-Oriented CNS Drug Manufacturers
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Acute Agitation Treatment Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Global Bi-level Positive Airway Pressure Devices (BiPAP) Market
5. BY PRODUCT
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
5.1.2. Market Attractiveness Index, By Product
5.2. Devices*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Fixed Pressure BiPAP Devices
5.2.4. Auto-adjusting BiPAP Devices
5.2.5. BiPAP ST (Spontaneous/Timed) Devices
5.2.6. BiPAP AVAPS Devices
5.2.7. Portable / Travel BiPAP Devices
5.2.8. ICU / Critical Care BiPAP Systems
5.2.9. Pediatric / Neonatal BiPAP Devices
5.2.10. Others
5.3. Masks
5.3.1. Full Face Masks
5.3.2. Nasal Masks
5.3.3. Nasal Pillow Masks
5.3.4. Total Face Masks
5.3.5. Pediatric Masks
5.3.6. Others
5.4. Aftermarket Parts and Accessories
5.4.1. Tubing / Breathing Circuits
5.4.2. Humidifiers
5.4.3. Filters
5.4.4. Headgear and Straps
5.4.5. Cushions and Mask Liners
5.4.6. Water Chambers
5.4.7. Batteries and Power Adapters
5.4.8. Carrying Cases
5.4.9. Others
6. BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Obstructive Sleep Apnea*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Central Sleep Apnea
6.4. Complex Sleep Apnea
6.5. Chronic Obstructive Pulmonary Disease (COPD)
6.6. Acute Respiratory Failure
6.7. Chronic Respiratory Failure
6.8. Neuromuscular Disorders
6.9. Obesity Hypoventilation Syndrome
6.10. Pneumonia and Other Respiratory Infections
6.11. Post-operative Respiratory Support
6.12. Others
7. BY TECHNOLOGY
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Integrated Humidification*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Heated Tubing
7.4. Smart Connectivity
7.5. Bluetooth-enabled Devices
7.6. Wi-Fi-enabled Devices
7.7. Cloud-based Monitoring
7.8. Telemonitoring Compatible Devices
7.9. Noise Reduction Technology
7.10. Pressure Relief Technology
7.11. Leak Compensation Systems
7.12. Touchscreen / Digital Interface
7.13. Others
8. BY PORTABILITY
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
8.1.2. Market Attractiveness Index, By Portability
8.2. Stationary Devices*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Portable Devices
8.4. Travel-friendly Devices
8.5. Others
9. BY PATIENT TYPE
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.1.2. Market Attractiveness Index, By Patient Type
9.2. Adult*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pediatric
9.4. Geriatric
10. BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic / Teaching Hospitals
10.4. Sleep Clinics and Sleep Laboratories
10.5. Home Healthcare Settings
10.6. Ambulatory Surgical Centers
10.7. Long-term Care Facilities
10.8. Rehabilitation Centers
10.9. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. US
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. UK
11.3.9.3. France
11.3.9.4. Russia
11.3.9.5. Italy
11.3.9.6. Spain
11.3.9.7. Norway
11.3.9.8. Netherlands
11.3.9.9. Sweden
11.3.9.10. Denmark
11.3.9.11. Belgium
11.3.9.12. Switzerland
11.3.9.13. Austria
11.3.9.14. Poland
11.3.9.15. Finland
11.3.9.16. Rest of Europe
11.4. Latin America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. Brazil
11.4.9.2. Argentina
11.4.9.3. Rest of Latin America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. China
11.5.9.2. India
11.5.9.3. Japan
11.5.9.4. Australia
11.5.9.5. South Korea
11.5.9.6. New Zealand
11.5.9.7. Indonesia
11.5.9.8. Malaysia
11.5.9.9. Philippines
11.5.9.10. Singapore
11.5.9.11. Thailand
11.5.9.12. Vietnam
11.5.9.13. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.6.9.1. UAE
11.6.9.2. Saudi Arabia
11.6.9.3. South Africa
11.6.9.4. Israel
11.6.9.5. Egypt
11.6.9.6. Turkey
11.6.9.7. Qatar
11.6.9.8. Kuwait
11.6.9.9. Oman
11.6.9.10. Bahrain
11.6.9.11. Rest of Middle East and Africa
12. COMPETITIVE LANDSCAPE ANALYSIS
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
12.4. Partner Identification Analysis
12.5. Investment & Funding Landscape
12.6. Strategic Alliances & Innovation Pipelines
13. COMPANY PROFILES
13.1. Pfizer, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Revenue Analysis
13.1.4. Pricing Analysis
13.1.5. SWOT Analysis
13.1.6. Recent Developments
13.1.6.1. Major Deals
13.1.6.2. M&A
13.1.6.3. Collaboration
13.1.6.4. Acquisition
13.1.6.5. Joint Ventures
13.1.6.6. Innovations
13.1.7. Recent News
13.1.7.1. Events
13.1.7.2. Conferences
13.1.7.3. Symposiums
13.1.7.4. Webinars
13.2. Otsuka Pharmaceutical Co., Ltd.
13.3. GlaxoSmithKline plc
13.4. H. Lundbeck A/S
13.5. Johnson & Johnson
13.6. Bristol-Myers Squibb Company
13.7. BioXcel Therapeutics, Inc.
13.8. Impel Pharmaceuticals Inc.
13.9. Lee Pharma Limited
13.10. Teva Pharmaceutical Industries Ltd.
13.11. Amneal Pharmaceuticals LLC
13.12. AbbVie Inc.
13.13. Aurobindo Pharma Limited
13.14. Apotex Inc.
13.15. F. Hoffmann-La Roche Ltd.
13.16. Hikma Pharmaceuticals PLC
13.17. Axsome Therapeutics, Inc.
13.18. Alkermes plc
13.19. Alexza Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE )
14. GLOBAL BI-LEVEL POSITIVE AIRWAY PRESSURE DEVICES (BIPAP) MARKET – RESEARCH METHODOLOGY
14.1. Research Data
14.1.1. Secondary Data
14.1.2. Primary Data
14.1.3. CAGR Analysis
14.2. Market Size Estimation Methodology
14.2.1. Bottom-Up Approach
14.2.2. Top-Down Approach
14.3. Market Breakdown & Data Triangulation
14.4. Research Assumptions
14.5. Limitations
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. EXECUTIVE SUMMARY
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising prevalence of psychiatric disorders and substance-induced agitation
3.1.1.2. Increasing emergency department visits related to acute behavioral disturbances
3.1.1.3. Growing adoption of rapid-acting and novel drug delivery formulations
3.1.2. Restraints
3.1.2.1. Safety concerns and adverse effects associated with antipsychotics and sedatives
3.1.2.2. Stringent regulatory scrutiny and post-marketing safety requirements
3.1.3. Opportunity
3.1.3.1. Development of non-invasive and fast-acting delivery systems (inhaled, intranasal, sublingual)
3.1.3.2. Increasing demand in emerging markets due to improving psychiatric care access
3.1.3.3. Pipeline development targeting agitation in dementia and Alzheimer’s disease
3.1.4. Trends
3.1.4.1. Shift toward atypical antipsychotics with improved safety profiles
3.1.4.2. Increasing preference for rapid-onset formulations in emergency psychiatry
3.1.5. Impact Analysis
4. INDUSTRY ANALYSIS
4.1. Porter’s Five Force Analysis – Global Bi-level Positive Airway Pressure Devices (BiPAP)
4.2. Geopolitical & Supply Chain Exposure
4.2.1. API Sourcing Concentration for Antipsychotics and Benzodiazepines
4.2.2. Trade Policies, Export Controls, and Psychiatric Drug Supply Risks
4.3. Social & Patient-Centric Factors
4.3.1. Physician Prescribing Behavior in Emergency Psychiatry and Acute Care
4.3.2. Brand Preference vs Generic Substitution Across Antipsychotics and Sedatives
4.3.3. Patient and Caregiver Concerns Regarding Sedation, Safety, and Monitoring
4.3.4. Awareness Gaps in Early Recognition and Management of Acute Agitation
4.4. Economic Factors
4.4.1. Reimbursement and Coverage in Hospital and Emergency Care Settings
4.4.2. Inflationary Pressure on APIs, Sterile Injectables, and CNS Drug Manufacturing
4.4.3. Currency Volatility Impacting Export-Oriented CNS Drug Manufacturers
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Acute Agitation Treatment Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Global Bi-level Positive Airway Pressure Devices (BiPAP) Market
5. BY PRODUCT
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
5.1.2. Market Attractiveness Index, By Product
5.2. Devices*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Fixed Pressure BiPAP Devices
5.2.4. Auto-adjusting BiPAP Devices
5.2.5. BiPAP ST (Spontaneous/Timed) Devices
5.2.6. BiPAP AVAPS Devices
5.2.7. Portable / Travel BiPAP Devices
5.2.8. ICU / Critical Care BiPAP Systems
5.2.9. Pediatric / Neonatal BiPAP Devices
5.2.10. Others
5.3. Masks
5.3.1. Full Face Masks
5.3.2. Nasal Masks
5.3.3. Nasal Pillow Masks
5.3.4. Total Face Masks
5.3.5. Pediatric Masks
5.3.6. Others
5.4. Aftermarket Parts and Accessories
5.4.1. Tubing / Breathing Circuits
5.4.2. Humidifiers
5.4.3. Filters
5.4.4. Headgear and Straps
5.4.5. Cushions and Mask Liners
5.4.6. Water Chambers
5.4.7. Batteries and Power Adapters
5.4.8. Carrying Cases
5.4.9. Others
6. BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Obstructive Sleep Apnea*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Central Sleep Apnea
6.4. Complex Sleep Apnea
6.5. Chronic Obstructive Pulmonary Disease (COPD)
6.6. Acute Respiratory Failure
6.7. Chronic Respiratory Failure
6.8. Neuromuscular Disorders
6.9. Obesity Hypoventilation Syndrome
6.10. Pneumonia and Other Respiratory Infections
6.11. Post-operative Respiratory Support
6.12. Others
7. BY TECHNOLOGY
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Integrated Humidification*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Heated Tubing
7.4. Smart Connectivity
7.5. Bluetooth-enabled Devices
7.6. Wi-Fi-enabled Devices
7.7. Cloud-based Monitoring
7.8. Telemonitoring Compatible Devices
7.9. Noise Reduction Technology
7.10. Pressure Relief Technology
7.11. Leak Compensation Systems
7.12. Touchscreen / Digital Interface
7.13. Others
8. BY PORTABILITY
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
8.1.2. Market Attractiveness Index, By Portability
8.2. Stationary Devices*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Portable Devices
8.4. Travel-friendly Devices
8.5. Others
9. BY PATIENT TYPE
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.1.2. Market Attractiveness Index, By Patient Type
9.2. Adult*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pediatric
9.4. Geriatric
10. BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic / Teaching Hospitals
10.4. Sleep Clinics and Sleep Laboratories
10.5. Home Healthcare Settings
10.6. Ambulatory Surgical Centers
10.7. Long-term Care Facilities
10.8. Rehabilitation Centers
10.9. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. US
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. UK
11.3.9.3. France
11.3.9.4. Russia
11.3.9.5. Italy
11.3.9.6. Spain
11.3.9.7. Norway
11.3.9.8. Netherlands
11.3.9.9. Sweden
11.3.9.10. Denmark
11.3.9.11. Belgium
11.3.9.12. Switzerland
11.3.9.13. Austria
11.3.9.14. Poland
11.3.9.15. Finland
11.3.9.16. Rest of Europe
11.4. Latin America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. Brazil
11.4.9.2. Argentina
11.4.9.3. Rest of Latin America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. China
11.5.9.2. India
11.5.9.3. Japan
11.5.9.4. Australia
11.5.9.5. South Korea
11.5.9.6. New Zealand
11.5.9.7. Indonesia
11.5.9.8. Malaysia
11.5.9.9. Philippines
11.5.9.10. Singapore
11.5.9.11. Thailand
11.5.9.12. Vietnam
11.5.9.13. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.6.9.1. UAE
11.6.9.2. Saudi Arabia
11.6.9.3. South Africa
11.6.9.4. Israel
11.6.9.5. Egypt
11.6.9.6. Turkey
11.6.9.7. Qatar
11.6.9.8. Kuwait
11.6.9.9. Oman
11.6.9.10. Bahrain
11.6.9.11. Rest of Middle East and Africa
12. COMPETITIVE LANDSCAPE ANALYSIS
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
12.4. Partner Identification Analysis
12.5. Investment & Funding Landscape
12.6. Strategic Alliances & Innovation Pipelines
13. COMPANY PROFILES
13.1. Pfizer, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Revenue Analysis
13.1.4. Pricing Analysis
13.1.5. SWOT Analysis
13.1.6. Recent Developments
13.1.6.1. Major Deals
13.1.6.2. M&A
13.1.6.3. Collaboration
13.1.6.4. Acquisition
13.1.6.5. Joint Ventures
13.1.6.6. Innovations
13.1.7. Recent News
13.1.7.1. Events
13.1.7.2. Conferences
13.1.7.3. Symposiums
13.1.7.4. Webinars
13.2. Otsuka Pharmaceutical Co., Ltd.
13.3. GlaxoSmithKline plc
13.4. H. Lundbeck A/S
13.5. Johnson & Johnson
13.6. Bristol-Myers Squibb Company
13.7. BioXcel Therapeutics, Inc.
13.8. Impel Pharmaceuticals Inc.
13.9. Lee Pharma Limited
13.10. Teva Pharmaceutical Industries Ltd.
13.11. Amneal Pharmaceuticals LLC
13.12. AbbVie Inc.
13.13. Aurobindo Pharma Limited
13.14. Apotex Inc.
13.15. F. Hoffmann-La Roche Ltd.
13.16. Hikma Pharmaceuticals PLC
13.17. Axsome Therapeutics, Inc.
13.18. Alkermes plc
13.19. Alexza Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE )
14. GLOBAL BI-LEVEL POSITIVE AIRWAY PRESSURE DEVICES (BIPAP) MARKET – RESEARCH METHODOLOGY
14.1. Research Data
14.1.1. Secondary Data
14.1.2. Primary Data
14.1.3. CAGR Analysis
14.2. Market Size Estimation Methodology
14.2.1. Bottom-Up Approach
14.2.2. Top-Down Approach
14.3. Market Breakdown & Data Triangulation
14.4. Research Assumptions
14.5. Limitations
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us